Global Point-of-Care or Rapid Diagnostics Device Market Size By Type (Blood Glucose Testing, Infectious Diseases Testing), By Application (Clinics, Hospitals), By Region, And Segment Forecasts, 2023 t...

The Global Point-of-Care (PoC) or Rapid Diagnostics Device Market was valued at USD 32.4 billion in 2023 and is projected to surpass USD 60.2 billion by 2031, growing at a CAGR of 8.3% during the forecast period (2023–2031). The surge in chronic and infectious diseases, coupled with increasing demand for immediate diagnostic results and decentralized healthcare delivery, are propelling the market. The adoption of PoC devices is transforming clinical workflows by enabling faster medical decisions, especially in critical care and rural settings with limited laboratory infrastructure.

Drivers:

1. Rising Prevalence of Chronic and Infectious Diseases

The growing incidence of conditions such as diabetes, cardiovascular diseases, HIV, and respiratory infections necessitates rapid diagnostics for timely treatment. PoC devices offer quick results, improving patient outcomes and disease management.

2. Technological Advancements and Miniaturization

Continuous innovation in biosensors, microfluidics, and AI integration has led to compact, accurate, and easy-to-use diagnostic devices. These advances are expanding PoC applications from traditional blood glucose monitoring to advanced infectious disease testing.

3. Demand for Decentralized Healthcare and Home Diagnostics

There is a shift from centralized diagnostics toward home and near-patient testing due to aging populations, increasing consumer health awareness, and pressure to reduce hospital readmissions and costs.

Restraints:

1. Regulatory and Quality Assurance Challenges

Stringent regulatory approval processes and varying compliance standards across regions can delay product launches and hinder adoption, especially in low- and middle-income countries.

2. Limited Reimbursement and Cost Concerns

Although PoC tests are faster, their high per-test cost compared to centralized lab testing, combined with inconsistent reimbursement policies, poses a barrier to widespread use.

Opportunity:

1. Expansion in Emerging Markets

Rapid urbanization, improved healthcare access, and government initiatives are boosting demand for PoC diagnostics in Asia-Pacific, Latin America, and parts of Africa.

2. Integration with Digital Health and Mobile Platforms

Linking PoC devices with smartphones and cloud systems enables remote diagnostics, telemedicine integration, and real-time monitoring, especially beneficial in rural or underserved areas.

Market by System Type Insights:

In 2023, the Lateral Flow Assay (LFA) segment dominated the market due to its simplicity, affordability, and broad application in infectious disease and pregnancy testing. Meanwhile, the molecular diagnostics segment is expected to witness the fastest growth during the forecast period, driven by the rising demand for COVID-19, tuberculosis, and sexually transmitted infection testing with high sensitivity and specificity.

Market by End-use Insights:

The Hospitals & Clinics segment accounted for the largest share in 2023 due to high patient footfall, the need for immediate treatment decisions, and better reimbursement structures. However, the Home Healthcare segment is projected to grow rapidly as consumer preference for self-monitoring and preventive care increases, supported by user-friendly device designs and smartphone integration.

Market by Regional Insights:

North America led the global market in 2023, driven by its advanced healthcare infrastructure, favorable reimbursement framework, and strong presence of key players. The Asia-Pacific region is expected to record the highest CAGR through 2031, supported by rising disease burden, increased healthcare spending, and expanding access to decentralized diagnostics in countries like India and China.

Competitive Scenario:

Key players in the Global Point-of-Care or Rapid Diagnostics Device Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Becton, Dickinson and Company, Danaher Corporation, Bio-Rad Laboratories, Quidel Corporation, Thermo Fisher Scientific, Chembio Diagnostics, and Sekisui Diagnostics. These companies are focusing on strategic partnerships, AI integration, and new product launches to cater to a broader range of diagnostic needs.

Scope of Work – Global Point-of-Care or Rapid Diagnostics Device Market

Report Metric Details

Market Size (2023) USD 32.4 Billion

Projected Market Size (2031) USD 60.2 Billion

CAGR (2023–2031) 8.3%

Market Segments By System Type (LFA, Molecular Diagnostics, Immunoassays), By End-use (Hospitals, Clinics, Home Healthcare, Research)

Growth Drivers Increasing chronic and infectious disease prevalence, demand for decentralized testing, and digital integration

Opportunities Market expansion in emerging economies, smartphone-integrated PoC diagnostics

Key Market Developments:

2023: Abbott launched a next-gen PoC molecular diagnostic platform with COVID-19 and influenza dual-detection capabilities.

2024: Roche Diagnostics partnered with a leading telemedicine firm to deliver remote testing solutions for chronic disease management.

2025: Siemens Healthineers introduced AI-powered PoC analyzers for enhanced diagnostic speed and accurac